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ThemicroRNA (miRNA) class of non-coding RNAs exhibit a diverse range of regulatory roles
in neuronal functions that are conserved from lower vertebrates to primates. Disruption of
miRNA expression has compellingly been linked to pathogenesis in neuropsychiatric and
neurodegenerative disorders, such as schizophrenia, Alzheimer’s disease, and autism.The
list of transcript targets governed by a single miRNA provide a molecular paradigm applica-
ble for therapeutic intervention. Indeed, reports have shown that speciﬁc manipulation of a
miRNA in cell or animal models can signiﬁcantly alter phenotypes linked with neurological
disease. Here, we review how a diverse range of biological systems, including Drosophila,
rodents, and primates such as monkeys and humans, can be integrated into the translation
of miRNAs as novel clinical targets.
Keywords: microRNAs, psychiatric, neurodegeneration, non-coding RNA, therapeutics, schizophrenia, mon-
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INTRODUCTION
The multi-functional role of RNA as a molecular regulator spans
a broad range of classiﬁcations as protein-coding and non-protein
coding RNA transcripts. Notably, the microRNA (miRNA) class
of non-coding RNAs have been implicated in a vast majority of
the established signaling cascades (Bartel, 2009). Brain-localized
miRNAs are of particular interest for neurological diseases which
have a complex etiology and no currently effective therapeutic
options. The transcriptomic targets of an miRNA can encompass
numerous cellular pathways, consistent with the extensive molec-
ular disruption linked to neurological disease onset. In this review,
we discuss how various model systems can be integrated into the
translation of miRNAs as novel clinical targets in the treatment of
neuropsychiatric and neurodegenerative disorders.
CONSERVED ROLE OF NEURONAL miRNAs
The conserved role of miRNAs in neuronal functions underscores
their relevance in the molecular dynamics between normal and
pathogenic mechanisms. Indeed, Drosophila, rodents, monkeys,
and humans have all shown signiﬁcant sensitivity to microRNA
modulation (Jin et al., 2004; Ashraf et al., 2006; Elmen et al.,
2008; Hollander et al., 2010). Notably, some core components of
the miRNA processing machinery, guided by the RNA-induced
silencing complex (RISC), are shared between lower vertebrates
and primates, such as the Argonaute-interacting proteins, GW182
(Chekulaeva and Filipowicz, 2009; Chekulaeva et al., 2011) and the
5′ pocket motif of the Dicer-homologs (Park et al., 2011). Further-
more, regulation of long-term memory processes and associated
synaptic proteins are controlled by the miRNA RISC pathway in a
diverse group of species (Ashraf et al., 2006; Rajasethupathy et al.,
2009; Gao et al., 2010; Konopka et al., 2010). Collectively, the pre-
vious reports indicate that epigeneticmodulation bymiRNAs are a
principal component to central nervous system development and
homeostasis.
Several of the more extensively reported brain-enriched miR-
NAs, such asmiR-9,miR-34,miR-124,miR-128,miR132,miR-219,
have predominantly identical mature sequences across species,
including humans, monkeys, mice, and Drosophila (Kapsimali
et al., 2007; Hu et al., 2011; Juhila et al., 2011). The conserva-
tion of those miRNAs spans from the 5′ seed region to the 3′ end
of the transcript.Moreover, the precursor sequence for some of the
brain-enriched miRNAs, including miR-9 and miR-124, are also
identical between humans and mice, further supporting a highly
conserved function for those transcripts.
miRNA REGULATION IN NEUROPSYCHIATRIC AND
NEURODEGENERATIVE DISORDERS
In the past few years, an extensive list of published reports have
emerged to support a signiﬁcant role formiRNAs in the pathogen-
esis of psychiatric andneurodegenerative disease (Bilen et al., 2006;
Lukiw, 2007; Hebert et al., 2008, 2009; Li et al., 2008, 2011; Wang
et al., 2009, 2010, 2011; Beveridge et al., 2010; Nelson and Wang,
2010; Nunez-Iglesias et al., 2010; Shioya et al., 2010; Chandrasekar
and Dreyer, 2011; Kocerha et al., 2011; Lee et al., 2011; Santarelli
et al., 2011; Smith et al., 2011; Liu et al., 2012b). The pathogenic
mechanisms underlying the development of psychiatric deﬁcits
and neurodegeneration are not always distinct, suggesting they
may be ideally suited for therapeutic targeting by pleiotropic miR-
NAs. Reports have shown that the precursor and mature miRNA
transcripts as well as the miRNA processing machinery itself, such
as Drosha and Dicer, are all subject to disruption with neurolog-
ical disease progression (Sun et al., 2009; Beveridge et al., 2010;
Babiarz et al., 2011; Fenelon et al., 2011; Schoﬁeld et al., 2011).
Notably, the miRNA-linked pathology can be provoked through
either genetic or non-genetic (sporadic) anomalies (Rademakers
et al., 2008; Kocerha et al., 2011).
Schizophrenia, autism, Fragile X syndrome, depression, addic-
tion, and anxiety are a few examples of psychiatric diagnoseswhere
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alteredmiRNAproﬁles have been identiﬁed, and a summary of the
dysregulated miRNAs and the biological source they were proﬁled
from are outlined in Table 1 (Jin et al., 2004; Abu-Elneel et al.,
2008; Li et al., 2008; Pietrzykowski et al., 2008; Hunsberger et al.,
2009;Yang et al., 2009; Zhou et al., 2009; Zhu et al., 2009; Beveridge
et al., 2010; Hollander et al., 2010; Im et al., 2010; Sarachana et al.,
2010; Saus et al., 2010; Xu et al., 2010a,b; Baudry et al., 2011a,b;
Eipper-Mains et al., 2011; Ghahramani Seno et al., 2011; Haramati
et al., 2011; Mouillet-Richard et al., 2011; O’Connor et al., 2011;
Shaltiel et al., 2012). In schizophrenia, miRNA proﬁling has now
been completed in several patient populations, primarily focused
within the cortex (Perkins et al., 2007; Beveridge et al., 2010; Kim
et al., 2010; Moreau et al., 2011; Santarelli et al., 2011). Although
a majority of the miRNA proﬁling studies for neurological dis-
ease have been performed from brain, miRNA dysregulation has
also been observed in other sources such as cerebral spinal ﬂuid
(CSF), plasma, serum, and peripheral blood (Schipper et al., 2007;
Cogswell et al., 2008; Gardiner et al., 2011; Ghidoni et al., 2011;
Lai et al., 2011). Beveridge andCairns (2011) recently reviewed the
various studies to compare and contrast the collection of miRNA
results in schizophrenia. Interestingly, a few of the miRNA fami-
lies, including the miR-15 and miR-30 families, have consistently
shown disruption in several of the population analyses (Beveridge
and Cairns, 2011). We examined the bioinformatic mRNA tar-
gets of miR-15 and miR-30 with Targetscan and found several
mRNAs which are strongly linked with schizophrenia, includ-
ing neuregulin and synaptotagmin (Kim et al., 2007; Kao et al.,
2010).
Psychiatric symptoms can also co-exist in patients with neu-
rodegenerative pathology, such as Huntington’s disease (HD),
Frontotemporal dementia (FTD), Alzheimer’s disease (AD),
Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS),
Table 1 | miRNAs associated with neuropsychiatric disease.
Disease Associated miRNAs Biological profiling source Reference
Schizophrenia 106b, 107, 128a, 134, 150, 15a, 15b, 16, 17, 181a, 181b,
195, 199a*, 19a, 20a, 20b, 212, 219, 24, 25, 26b, 27a,
29a, 29b, 29c, 30a-5p, 30b, 30d, 30e, 328, 346, 382,
487a, 9-3p, 92, let-7d, let-7e, 652, 7
Human cortex (temporal and
prefrontal)
Beveridge et al. (2008, 2010), Zhu et al.
(2009), Perkins et al. (2007), Santarelli et al.
(2011)
219 Cortex from mouse model of
schizophrenia
Kocerha et al. (2009)
137, 30e Human genomic DNA Ripke et al. (2011), Xu et al. (2010a)




106b, 132*, 132, 133b, 138, 140-3p, 145*, 145, 148b,
151, 154*, 15a, 181a, 186, 190, 192, 193a, 193b, 210,
212, 22*, 22, 27b, 29a, 301, 32, 324-3p, 33, 330, 338,
339, 34a, 425, 454*, 504, 520c-3p, 544, 545, 573, 639,
7, 767-5p, 874, 889, 99a
Human cortex Moreau et al. (2011), Kim et al. (2010)
Autism 106a, 106b, 128, 129, 132, 140, 146b, 148b, 15a, 15b,
181d, 193b, 21, 212, 23a, 27a, 320a, 381, 431, 432,
484, 539, 550, 598, 652, 7, 93, 95
Human cerebellum Abu-Elneel et al. (2008)
103, 106b, 107, 10a, 125b, 132, 133b, 136, 139, 148b,
153-1, 16-2, 182-AS, 185, 186, 189, 190, 191, 194, 195,
196a, 199a-5p, 199b, 199b-5p, 205, 211, 219, 23a, 23b,
25, 29b, 30c, 326, 338-3p, 346, 367, 376a-AS, 451, 455,
455-3p, 486-3p, 486-5p, 495, 518a, 519c, 520b, 524,
577, 650, 93
Lymphoblastoid cell lines Sarachana et al. (2010), Ghahramani Seno
et al. (2011)
Depression 16 Mouse serotonergic raphe
nuclei
Baudry et al. (2011a,b)
182, 30e Human genomic DNA (blood) Saus et al. (2010), Xu et al. (2010b)
101, 10a, 130a, 137, 142-3p, 142-5p, 146a, 148b, 155,
190, 20a, 20b, 27a, 301a, 324-5p, 335, 376a*, 489, 494,
497, 660
Human prefrontal cortex Smalheiser et al. (2012)
Addiction 212, 132, 124, let-7d, 181a Brain tissue from rat cocaine
addiction model
Hollander et al. (2010), Chandrasekar and
Dreyer (2011)
103, 125b-5p, 127, 138, 181a, 24, 26a, 29a, 29b, 30a,
30c, 30d, 30e, 7a, 7b, 7c, 7c, 9, let-7a, let-7f, let-7g
Brain tissue from mouse
cocaine addiction model
Eipper-Mains et al. (2011)
9 Striatal neuronal cultures for
model of alcohol exposure
Pietrzykowski et al. (2008)
Anxiety 132, 34 Brain tissue from mouse model
of anxiety
Shaltiel et al. (2012), Haramati et al. (2011)
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all of which have shown miRNA disruption and is summarized
in Table 2 (Wang et al., 0000; Hebert et al., 2008; Packer et al.,
2008; Hebert and De Strooper, 2009; Williams et al., 2009; Hara-
mati et al., 2010; Jiao et al., 2010; Lau and de Strooper, 2010;
Buckley and Johnson, 2011; Gaughwin et al., 2011; Kocerha
et al., 2011; Lee et al., 2011; Martins et al., 2011; Minones-
Moyano et al., 2011; Smith et al., 2011; Enciu et al., 2012;
Mouradian, 2012). A pivotal role for miRNAs in neurodegen-
erative disease is further supported by numerous reports link-
ing miRNAs with neurogenesis and neurodegenerative signaling
cascades, and thus, overall neuronal density (Patel et al., 2008;
Boissonneault et al., 2009; Gao, 2010; Magill et al., 2010; Schon-
rock et al., 2010; Shi et al., 2010; Cho et al., 2011; Shibata
et al., 2011; Tao et al., 2011; Han et al., 2012; Persengiev et al.,
2012).
SomemiRNAs, such asmiR-132, have been shown to be dysreg-
ulated in both psychiatric and neurodegenerative disease.miR-132
has been linked with schizophrenia (Perkins et al., 2007; Kim et al.,
2010), addiction (Hollander et al., 2010), HD (Lee et al., 2011),
AD (Cogswell et al., 2008), and progressive supranuclear palsy
(PSP; Smith et al., 2011). Indeed, the wide range of neurologi-
cal diseases in which miR-132 is disrupted is consistent with its
principal role in neuronal plasticity and related functions (Magill
et al., 2010; Remenyi et al., 2010; Mellios et al., 2011; Shaltiel et al.,
2012).
NON-PRIMATE MODELS AND miRNA THERAPEUTIC
DISCOVERY
A selection of cell and animal models have been engaged in the
preliminary search for miRNAs with clinical relevance for neu-
rological disease. Cell lines, primary cell cultures, differentiated
neurons, and induced pluripotent stem (iPS) cells are a few of the
platforms that have effectively been utilized for in vitro analyses
(Cole et al., 2008; Agostini et al., 2011; Arias-Carrion and Salama,
2011; Kim et al., 2011; Saba et al., 2012). Indeed, cell-based sys-
tems have led to successful large-scale screening studies as well as
in-depthmolecular analysis of functional miRNAs (Vo et al., 2005;
Cole et al., 2008; Connelly et al., 2012). For example, the discovery
that neuronally enriched miR-132 is regulated by cAMP-response
element binding protein (CREB) was initiated through a genome-
wide screen in rat PC12 neuronal cells (Vo et al., 2005). Not all
miRNAs will have a functional biological role, however, cell-based
screens can facilitate the identiﬁcation of promising candidates.
In parallel with the in vitro ﬁndings, studies in non-primate
animal models have signiﬁcantly advanced our understanding
of miRNA biology in psychiatric and neurodegenerative disor-
ders (Kocerha et al., 2009; Hollander et al., 2010; Lee et al.,
2011; Li et al., 2011). Animal studies are a critical step in
the progression toward testing of miRNA-based therapeutics in
clinical trials. Our group examined the regulation of miRNAs
in mice with pharmacological induction of a schizophrenia-
associated behavioral phenotype (Kocerha et al., 2009). Likewise,
a neurotoxin induced mouse model (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine; MPTP) for Parkinson’s disease (PD) was used
to uncover a role for miR-7 in PD pathology (Junn et al., 2009). In
addition to pharmacologically treated animal models, transgenic,
knock-out and knock-in mice have also been valuable in vivo
resources (Lee et al., 2011; Tao et al., 2011). Indeed, transgenic
expression of the AD-causative amyloid precursor protein (APP)
gene in mice provoked signiﬁcant disruption in neuronal miRNA
expression (Schonrock et al., 2010).
In addition to mice, rats as well as zebraﬁsh and other verte-
brate species have been integral in the study of neuronal miRNA
pathways prior to testing in primate models (Yang et al., 2011; Tal
et al., 2012). Indeed, recent reports identiﬁedmiRNAs in zebraﬁsh
directly linked to neurobehavioral responses and neuronal dif-
ferentiation (Tal et al., 2012). The exploration of miRNAs which
regulate central nervous system functions, however, is not lim-
ited to vertebrate species. Drosophila, an invertebrate model, have
been widely used for many years to examine or further deﬁne
molecular mechanisms. Moreover, studies in Drosophila recently
revealed that the conserved miRNA miR-34 mediates aging and
neurodegenerative processes (Liu et al., 2012a), further substanti-
ating that all biological models are applicable in the investigation
of non-coding RNAs. Additionally, as each miRNA may regulate
a number of transcripts and therefore off-target effects may result
when altered, animal and cell models may help to ﬁlter out those
candidates.
PRIMATE MODELS AND miRNA PRE-CLINICAL EVALUATION
Arguably, a principal goal in the ﬁeld of non-coding RNAs, includ-
ing miRNAs, is to uncover transcripts which can ultimately lead
to advancements in human health. Correspondingly, there are
numerous studies which have proﬁled miRNA expression from
humans with and without a disease diagnosis. Although some
of those reports have focused on peripheral tissues, a subset of
those analyses have speciﬁcally examined miRNA transcripts in
distinct brain regions (Hebert et al., 2008; Kocerha et al., 2011;
Santarelli et al., 2011). Genome-wide association (GWAS) studies
and microarray proﬁling have both been used to identify miRNAs
which are potential disease risk factors for neurodegenerative and
psychiatric disorders (Rademakers et al., 2008; Hollander et al.,
2010; Kocerha et al., 2011; Richardson et al., 2011; Ripke et al.,
2011). Furthermore, there can be disruption of a cluster or mul-
tiple members within an miRNA family, such as with miR-29. In
brain tissue from a cohort of Alzheimer’s patients, miR-29a and
miR-29b expression were both signiﬁcantly repressed in patients
with increased levels of beta-secretase/BACE1 (Hebert et al., 2008).
BACE1 is a direct mRNA target for the miR-29 family and has
consistently been linked to AD pathology. Therefore, correlation
of expression for a miRNA and its targets in the transcriptome,
as well as identiﬁcation of disruption in miRNA families, can all
contribute to effective discovery of new treatment alternatives for
diagnosed patients.
The brain structure and related functions of humans andmon-
keys are strikingly similar (King andWilson, 1975;McConkey and
Varki, 2000; Paabo, 2001; Perkins et al., 2010; de Araujo et al.,
2012), suggesting that monkeys are a relevant primate model
for pre-clinical investigation of miRNAs in neurological dysfunc-
tion. Notably, certain key cell types in the brain linked to disease
pathology, such as mirror neuron disruption in autism (Perkins
et al., 2010), are primarily speciﬁc to primate physiology. More-
over, there is extensive conservation inmiRNAs between primates,
including those which are localized in the central nervous system
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Table 2 | miRNAs associated with neurodegenerative disease.
Disease Associated miRNAs Biological profiling source Reference
Huntington’s
disease (HD)
100, 125b, 127-3p, 135a, 135b, 138, 145, 146, 146a,
148a, 150, 181c, 190, 199a-3p, 199a-5p, 200a, 205, 214,
218, 221, 222, 335, 338-3p, 9*, 9
Huntington cell lines Ghose et al. (2011), Sinha et al. (2010)
34b Human plasma Gaughwin et al. (2011)
1-1, 124a, 128, 132, 133a, 135b, 138, 203, 204, 21, 218,
22, 222, 29a, 29b-1, 29c, 330, 344, 346, 674*, 9-1, 9-3
Brain tissue from trans-
genic HD mice
Lee et al. (2011), Johnson et al. (2008)
100, 151, 16, 219-2-3p, 27b, 451, 92a, 128, 139-3p, 222,
382, 433, 485-3p, 9, 9*, 29b, 124a, 132
Human brain regions Marti et al. (2010), Packer et al. (2008)
Frontotemporal
dementia (FTLD)
922, 516a-3p, 571, 548b-5p, 548c-5p Human cortex and cerebel-
lum
Kocerha et al. (2011)
29b, 107 Cell cultures Wang et al. (2010), Jiao et al. (2010)
659 Human genomic DNA Rademakers et al. (2008)
Parkinson’s dis-
ease (PD)
1, 126*, 126, 147, 151-3p, 151-5p, 16-2*, 199a-3p, 19b,
22*, 26a, 26a2*, 28-5p, 29a, 29b, 29c, 301a, 30a, 30b,
30c, 335, 374a, 374b
Human blood Martins et al. (2011), Margis and Rieder. (2011)
34b, 34c, 133b Human brain Minones-Moyano et al. (2011), Kim et al. (2007)
50, 83, 58, 77, 238, 1, 48, 65, 64, 80, 84, let-7, 236, 51,
241, 230,
C. elegans Asikainen et al. (2010)
10a, 10b, 212, 132, 495 Mouse model for PD Gillardon et al. (2008)




206 Mouse model for ALS Williams et al. (2009)
Alzheimer’s dis-
ease (AD)
137, 181c, 9, 29a, 29b, 34a, 181b Human blood Geekiyanage et al. (2011), Schipper et al. (2007)
137, 181c, 9, 29a, 29b Human serum Geekiyanage et al. (2011)
101, 106b, 107, 125b, 137, 142-3p, 142-5p, 145, 151-
5p, 15a, 181c, 184, 185, 194, 197, 19b, 210, 212, 214,
219-2-3p, 22, 223, 26b, 27b, 298, 29a, 29a/b-1, 29b-1,
300, 301a, 320, 326, 330-5p, 338-3p, 338-5p, 361-3p,
363, 382, 424, 425, 509-5p, 511, 516a-5p, 516b, 525-5p,
551b, 576-5p, 583, 9, 93, 98, let-7e, let-7f, let-7i
Human cortex Wang et al. (2011), Hebert et al. (2008), Shioya
et al. (2010), Nelson andWang (2010), Geekiyan-
age and Chan (2011)
9, 125b, 128, 124a Human hippocampus Lukiw (2007)
105, 10a, 10b, 125a, 126*, 126, 127, 135a, 138, 141,
142-5p, 143, 146b, 151, 154, 15b, 181a, 181c, 186, 191,
194, 195, 197, 199a*, 204, 205, 214, 216, 221, 302b,
30a-3p, 30a-5p, 30b, 30c, 30d, 32, 338, 345, 362, 371,
374, 375, 380-3p, 422b, 429, 448, 449, 451, 455, 494,
497, 501, 517a, 517b, 518b, 518f, 520a*, 526a, 7f, 99a
Human CSF Cogswell et al. (2008)
125b, 106b, 107, 124, 132, 145, 146b, 148a, 17-5p, 200c,
20a, 210, 212, 26a, 27a, 27b, 30c, 30e-5p, 34a, 381,
422a, 423, 425, 9, 92, let-7b, 100
Human brain Cogswell et al. (2008), Hebert et al. (2009),
Smith et al. (2011), Wang et al. (2008)
106a, 106b, 125b, 137, 146a, 147, 148b, 153, 17, 17-5p,
181c, 187, 20a, 20b, 21, 212, 26a, 27a, 298, 301, 30b,
30c, 30e-5p, 323-3p, 328, 34a, 361, 365, 376b, 381,
409, 422a, 423, 433, 520c, 644, 655, 664, 700, 7g, 7i,
9, 92
Cell cultures Long and Lahiri. (2011), Kim et al. (2011), Bois-
sonneault et al. (2009), Patel et al. (2008),
Schonrock et al. (2010), Delay et al. (2011),
Hebert et al. (2009), Smith et al. (2011)
34a, 103, 107, 146a, 106b, 16, 34c, 20a, 17-5p AD mice models
Yao et al. (2010), Li et al. (2011), Wang et al.
(2009, 2010), Liu et al. (2012b), Zovoilis et al.
(2011), Hebert et al. (2009)





Mallick and Ghosh. (2011)
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(Brameier, 2010; Hu et al., 2011). One recent study reported that
of the 413 miRNAs expressed in human brain, 366 of those tran-
scripts are also detectable in rhesus macaque brain (Hu et al.,
2011). Correspondingly, a number of those miRNAs are also
detectable in mouse cortex and hippocampus by microarray and
sequencing efforts, such as miR-9, miR-124, miR-128, and miR-
132 (Juhila et al., 2011), suggesting that mouse models can be
effective prior to testing in primates.
There have been considerable technological advancements in
recent years with primate focused research, including with non-
coding RNAbiology. Groups have successfully deliveredmodiﬁed-
antisense oligonucleotides (ASO) into monkeys to inhibit the
function of speciﬁc miRNAs with minimal off-target effects
(Elmen et al., 2008; Petri et al., 2009; Lanford et al., 2010). To
date, the ability to modulate miRNAs in primates is restricted to
peripheral administration, however, delivery of potential thera-
peutics across the blood brain barrier could be a future attainable
milestone. Progress has also been made in other capacities with
primates, including with the generation of transgenic monkeys.
Our group established the ﬁrst transgenic rhesus macaques in
2001 (Chan et al., 2001), which subsequently led to the devel-
opment of a cohort for HD transgenic monkeys (Yang et al.,
2008), a resource directly applicable to assess miRNA functions
in a primate model of neurodegenerative disease. Moreover, from
the HD monkeys we derived iPS cells which display a pro-
gressive cellular phenotype (Chan et al., 2010), providing an
in vitro platform to complement the in vivo analyses for ther-
apeutic and biomarker discovery, including non-coding RNA
targets.
In primates, the progression of neurodegeneration and psy-
chiatric deﬁcits is typically gradual, developing over years, rather
than weeks or months. Correspondingly, longitudinal analyses of
molecular and neurobehavorial changes are fundamental to the
monitoring and subsequent discovery of new treatments (Insel,
2009; Thompson et al., 2011). Indeed, longitudinal studies are
readily implementable in primate species such as monkeys and
humans, including collection of peripheral blood samples for
molecular analysis throughout disease progression and parallel
correlation with brain morphology by magnetic resonance imag-
ing (MRI; Thompson et al., 2011; Waber et al., 2012; Zhang et al.,
2012). The correlation of miRNA expression with disease trajec-
tories may help identify functional non-coding RNA transcripts
involved in neuronal pathogenesis.
APPROACHES FOR miRNA MODULATION AND CLINICAL
TRANSLATION
As discussed above, a considerable number of in vitro and in vivo
models are increasingly becoming available for miRNA func-
tional studies. In conjunction, there have also been signiﬁcant
advances in the approaches tomodulate or detect speciﬁcmiRNAs.
Viral and antisense-mediated targeting of non-coding transcripts
are routinely applied to alter expression levels, however, techni-
cal improvements have allowed for increased effectiveness and
efﬁcacy. For example, locked nucleic-modiﬁed antisense oligonu-
cleotides (LNA-ASO) signiﬁcantly enhance the speciﬁcity and
stability of miRNA silencing (Elmen et al., 2008; Stenvang et al.,
2008;Kocerha et al., 2009;Hollander et al., 2010;Obad et al., 2011).
Notably, the LNA-ASO can be administered in vivo to animal
models through different routes, such as intracerebroventricu-
lar (icv) delivery to penetrate multiple brain regions (Kocerha
et al., 2009; He et al., 2010), or local stereotactic injections for
site-speciﬁc miRNA silencing (Gao et al., 2010; Hollander et al.,
2010). LNA-modiﬁed probes also intensify the detectability of
non-coding RNAs for in situ localization (Havelda, 2010), which
facilitates examination of less abundant transcripts. There are
other chemical modiﬁcations available for ASO, such as 2′-O-
methyl RNA, 2′-O-methyloxyethyl RNA, and phosphorothioate
RNA (Ruberti et al., 2011), some of which have also been suc-
cessfully utilized in the context of in vivo silencing (Cheng et al.,
2009).
In addition to viral and antisense methods, nanoparticle deliv-
ery of neurogenic miRNAs provide a means for brain distribution
of selected transcripts. Just recently, reports showed that rabies
virus glycoprotein (RGV)-labeled nanomaterials resulted in spe-
ciﬁc delivery of miR-124 to neuronal cells (Hwang do et al.,
2011). Nanotechnology has also been employed to silence miRNA
function, such as with miR-122 conjugated to gold nanoparti-
cles in myeloma cells (Crew et al., 2012), suggesting this tech-
nology is effective in the repression or stimulation of miRNA
expression.
Importantly, silencing of miRNAs in animal embryos have
also provided signiﬁcant insight to their role in brain develop-
ment. Recent reports have shown that injection of morpholi-
nos to block miR-9 activity in the embryos of Xenopus trop-
icalis (Bonev et al., 2011) or zebraﬁsh (Tal et al., 2012) sub-
stantially altered neuronal functions in the developing animals.
Furthermore, overexpression or silencing of miR-9 via electropo-
ration in mouse embryos revealed that Cajal Retzius neuronal
cell differentiation is regulated through Forkhead box protein
G1 (FOXG1; Shibata et al., 2008). Collectively, these reports
indicate that miRNA activity can be modulated in vivo at var-
ious developmental stages to assess their implications in brain
functions.
Overall, the technical developments in miRNA biology men-
tioned above facilitate the translation of select miRNA transcripts
for future clinical intervention. Indeed, there are human trials
currently being conducted to assess miRNA-modulation in dis-
ease pathogenesis, including the use of LNA-ASO (Seto, 2010;
Montgomery and van Rooij, 2011). To date, the reported human
trials have focused on miRNA regulation in peripheral organs,
however, therapeutic targeting of the brain remains a future objec-
tive. Polymer (Cheng and Saltzman, 2012), lipid (Shi et al., 2012),
and polylysine (Jin et al., 2012) based nanoparticle modulation
of miRNAs has also been reported. Although a majority of the
nanodelivery methods for miRNA studies have focused on non-
neuronal cells, there is great potential for their application to the
central nervous system.
CONCLUSION
The discovery and development of miRNA-based therapeutics, as
well as the diverse range of molecular cascades they can regu-
late, offer a new approach for treating diseases with a heterogeneic
or epigenetic origin. There are numerous psychiatric and neu-
rodegenerative diseases with no effective treatments due to their
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complex etiology and therefore may be ideally positioned for
clinical targeting of pleiotropic miRNAs.
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